May 1 (UPI) --Pharmaceutical giant Johnson & Johnson on Wednesday said it is taking steps to resolve a multibillion dollar, cancer-related lawsuit with thousands of individuals over claims that ...
Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news ...
J&J will buy Momenta Pharmaceuticals for roughly $6.5 billion in cash, paving the way for its Janssen unit to expand its efforts into autoimmune disease treatments. J&J will pay $52.50 for each ...
Johnson and Johnson reiterated in its statement on Wednesday, May 1, that “none of the talc-related claims against it have ...
Pharmaceutical giant Johnson & Johnson is set to pay $6.475 billion to settle lawsuits alleging its talc-based products, often associated with health concerns, caused cancer. This unprecedented ...
Benzinga - by Vandana Singh, Benzinga Editor. Wednesday, Johnson & Johnson (NYSE:JNJ) announced its intention to proceed with a $ ...
Johnson & Johnson Wants To Deal With Talc Lawsuit Overhang, Proposes $6.5B Settlement Package Mi Aktien New York: Anleger etwas erleichtert nach US-Zinsentscheid ...
Johnson & Johnson Ordered To Pay $260M In Latest Talc Trial The ruling comes as J&J continues to pursue a proposed $6.48 billion settlement of most talc-related lawsuits through a prepackaged ...
NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (AMAM), in an all-cash merger deal for a total equity value of ...
Johnson & Johnson is ordered to pay a $300 million punitive award to a woman who said she contracted cancer through the use of the company's talc-based products. Johnson & Johnson is ordered to ...
Johnson & Johnson said it would acquire Proteologix for $850 million as it looks to gain access to the privately held company’s experimental atopic dermatitis treatments. Proteologix’s ...